Connect your AI

Cytokinetics CYTK SG&A

SG&A at other companies

Bristol-Myers SquibbBMY

$1.62B+2.1%

Eli LillyLLY

$2.93B+18.9%

Merck & Co.MRK

$2.7B+5.8%

BioMarin PharmaceuticalsBMRN

$258.29M+25.3%

MedtronicMDT

$3.06B+12.4%

Boston ScientificBSX

$1.78B+11.5%

Other financials

Income statement

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cytokinetics's SG&A?: Cytokinetics (CYTK) reported SG&A of $104.9M in Q1 2026.